<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571321</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-1110</org_study_id>
    <nct_id>NCT03571321</nct_id>
  </id_info>
  <brief_title>Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will&#xD;
      be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute&#xD;
      lymphoblastic leukemia (ALL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">September 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of adding ruxolitinib to a standard-of-care pediatric-based chemotherapy regimen in adolescents and young adult patients as determined by rate of side effects seen when combination is given</measure>
    <time_frame>24 weeks</time_frame>
    <description>Determined by rate of side effects seen when combination is given</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participants that are minimal residual disease (MRD) negative at end of induction therapy</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>ALL, Childhood</condition>
  <condition>ALL</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ruxolitinib in addition to standard chemotherapy.&#xD;
Standard Chemotherapy Consists of:&#xD;
Remission consolidation therapy (lasting 8 weeks)&#xD;
Interim Maintenance (lasting 8 weeks)&#xD;
Delayed Intensification (lasting 8 weeks&#xD;
Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)&#xD;
Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Participants will receive one of 3 doses [taken by mouth] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.&#xD;
Remission consolidation regimen:&#xD;
Days 1-14 and 29-43&#xD;
Interim maintenance regimen:&#xD;
Days 1-14 and 29-43&#xD;
Delayed Intensification regimen:&#xD;
Days 1-14 and 29-43</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <other_name>Jakafi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Remission consolidation regimen:&#xD;
1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29&#xD;
Delayed Intensification regimen:&#xD;
1000 mg/m2 IV on Day 29</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Remission consolidation regimen:&#xD;
75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39&#xD;
Delayed Intensification regimen:&#xD;
75 mg/m2/day IV or SC on Days 29-32 and 36-39</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Taken by mouth.&#xD;
Remission consolidation regimen:&#xD;
60 mg/m2 on Days 1-14 and 29-42&#xD;
Maintenance Therapy:&#xD;
75 mg/m2 on Days 1-84</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Remission consolidation regimen:&#xD;
1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50&#xD;
Interim maintenance regimen:&#xD;
1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41&#xD;
Delayed Intensification regimen:&#xD;
1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50&#xD;
Maintenance Therapy:&#xD;
1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Remission consolidation regimen:&#xD;
2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43&#xD;
Interim maintenance regimen:&#xD;
2500 IU/m2 IM or IV on Days 2 and 22&#xD;
Delayed Intensification regimen:&#xD;
2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43.</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.&#xD;
Remission consolidation regimen:&#xD;
375 mg/m2 IV on Days 1, 8, 29 and 36&#xD;
Interim maintenance regimen:&#xD;
375 mg/m2 IV on Days 1 and 11&#xD;
Delayed Intensification regimen:&#xD;
375 mg/m2 IV on Days 1 and 8</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (Intrathecal Administration)</intervention_name>
    <description>Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal [IT] administration).&#xD;
Remission consolidation regimen:&#xD;
15 mg on Days 1, 8, 15, and 22&#xD;
Interim maintenance regimen:&#xD;
15 mg on Days 1 and 31&#xD;
Delayed Intensification regimen:&#xD;
15 mg on Days 1, 29, and 36&#xD;
Maintenance Therapy:&#xD;
15 mg on Day 1&#xD;
15 mg on Day 29 (First 4 courses only)</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (Intravenous Administration)</intervention_name>
    <description>Interim maintenance regimen:&#xD;
100 mg/m2 IV on Days 1, 11, 21, 31, and 41</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Taken by mouth or given by IV infusion.&#xD;
Delayed Intensification regimen:&#xD;
10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21&#xD;
Maintenance Therapy:&#xD;
6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Delayed Intensification regimen:&#xD;
25 mg/m2 IV on Days 1, 8, 15</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>Taken by mouth at least 1 hour after evening meal.&#xD;
Delayed Intensification regimen:&#xD;
60 mg/m2 on Days 29-42</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate Oral Product</intervention_name>
    <description>Taken by mouth.&#xD;
Maintenance Therapy:&#xD;
20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)&#xD;
Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given]</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed de novo B-precursor acute lymphoblastic leukemia (ALL) as determined&#xD;
             by World Health Organization (WHO) criteria. Patients must have unequivocal diagnosis&#xD;
             of precursor B ALL. This includes an institutional immunophenotyping report that is to&#xD;
             assign B-lineage or T-lineage.&#xD;
&#xD;
          -  &quot;Ph-like&quot; signature, as determined by low density micro-array (LDA) card&#xD;
&#xD;
          -  Jak-targetable genetic signature as defined by any of the following:&#xD;
&#xD;
               -  Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type)&#xD;
&#xD;
               -  JAK2 or erythropoietin receptor (EPOR) fusions.&#xD;
&#xD;
               -  Other JAK pathway alterations at the discretion of the principle investigator&#xD;
                  including, but not limited to:&#xD;
&#xD;
          -  SH2B adaptor protein 3 (SH2B3) deletions&#xD;
&#xD;
          -  Interleukin-7 receptor subunit alpha (IL7RA) mutations&#xD;
&#xD;
          -  Prior therapy&#xD;
&#xD;
               -  Prior to starting ruxolitinib, patients must have completed a 4-drug induction&#xD;
                  regimen with intrathecal chemotherapy (modified aBFM regimen or equivalent) as&#xD;
                  per the institutional standard of care. Recommended induction treatment is&#xD;
                  outlined in Section 5.1.2.&#xD;
&#xD;
               -  No additional prior therapy for acute leukemia except emergency therapy&#xD;
                  (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava&#xD;
                  syndrome, or renal failure due to leukemic infiltration of the kidneys. When&#xD;
                  indicated, leukapheresis or exchange transfusion is recommended to reduce the&#xD;
                  white blood cell count (WBC).&#xD;
&#xD;
               -  Screening may occur at any point prior to or during induction therapy&#xD;
&#xD;
          -  Age ≥ 18 years and &lt; 40 years. Because this is specifically a study of the adolescent&#xD;
             and young adult population and no adverse event data are currently available on the&#xD;
             use of this pediatric-based chemotherapy regimen in patients ≥ 40 years of age, older&#xD;
             adults are excluded from this study, but may be eligible for future trials.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥ 60%)&#xD;
&#xD;
          -  Platelet count &gt; 25,000/uL.&#xD;
&#xD;
          -  Patients must have normal organ function as defined below:&#xD;
&#xD;
               -  total bilirubin ≤ 2 mg/dL&#xD;
&#xD;
               -  aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5 ×&#xD;
                  institutional upper limit of normal&#xD;
&#xD;
               -  creatinine within normal institutional limits OR creatinine clearance ≥ 60&#xD;
                  mL/min/1.73 m2 for patients with creatinine levels above institutional normal.&#xD;
&#xD;
          -  Because the therapeutic agents used in this study are known to be teratogenic, women&#xD;
             of child-bearing potential and men must agree to use adequate contraception (hormonal&#xD;
             or barrier method of birth control; abstinence) prior to study entry and for the&#xD;
             duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while she or her partner is participating in this study, she should inform&#xD;
             her treating physician immediately. Men treated or enrolled on this protocol must also&#xD;
             agree to use adequate contraception prior to the study, for the duration of study&#xD;
             participation.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are receiving any other investigational agent.&#xD;
&#xD;
          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancers. Patients are not considered to have a &quot;currently active&quot; malignancy if they&#xD;
             have completed therapy and are free of disease for ≥ 3 years.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to ruxolitinib or other agents used in study.&#xD;
&#xD;
          -  Use of any potent cytochrome P450 (CYP) 3A4 inhibitor or inducer within 5 half-lives&#xD;
             before the first dose of the study drug. Potent inhibitors of CYP3A4 include systemic&#xD;
             ketoconazole, posaconazole, voriconazole, clarithromycin, itraconazole, nefazodone,&#xD;
             and telithromycin. At the fluconazole dose of 200mg daily used this regimen, there is&#xD;
             minimal inhibition of CYP3A4 [36] and therefore fluconazole is not prohibited on this&#xD;
             trial and no dose modifications should be made in the presence of fluconazole.&#xD;
&#xD;
        Because the lists of these agents are constantly changing, it is important to regularly&#xD;
        consult a frequently-updated list such as&#xD;
        http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the&#xD;
        Physicians' Desk Reference may also provide this information. As part of the&#xD;
        enrollment/informed consent procedures, the patient will be counseled on the risk of&#xD;
        interactions with other agents, and what to do if new medications need to be prescribed or&#xD;
        if the patient is considering a new over-the-counter medicine or herbal product.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Pregnant women are excluded from this study because ruxolitinib is a class C agent&#xD;
             with the potential for teratogenic or abortifacient effects. Because there is an&#xD;
             unknown but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother with ruxolitinib breastfeeding should be discontinued if the&#xD;
             mother is treated with ruxolitinib. These potential risks may also apply to other&#xD;
             agents used in this study.&#xD;
&#xD;
          -  Down Syndrome due to the likelihood of excessive toxicity resulting. These patients&#xD;
             should be treated in consultation with a pediatric oncologist.&#xD;
&#xD;
          -  Burkitt type leukemia&#xD;
&#xD;
          -  Ph+ ALL at time of diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Stock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Office</last_name>
    <phone>1-855-702-8222</phone>
    <email>cancerclinicaltrials@bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howie Weiner</last_name>
      <phone>773-702-2084</phone>
      <email>hweiner@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Wendy Stock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

